Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Annals of Hematology

Open Access 17-01-2025 | Lymphoma | Review

Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis

Authors: Xijing Li, Yang Lin, Licai An

Published in: Annals of Hematology

Login to get access

Abstract

This meta-analysis aimed to assess the impact of genetic mutations, particularly in the NOTCH2 and TNFAIP3 genes, on the prognostic outcomes of Marginal Zone Lymphoma (MZL) patients. Databases, including PubMed, Embase, and Cochrane Library, were explored up to October 2023. A total of 11 studies encompassing 2,314 records were included. Outcome measures were 5-year overall survival rates (OSR), progression-free survival rates (PFSR), and tumor progression rates (TPR). NOTCH2 and TNFAIP3 mutations were prominently identified across studies. In splenic MZL (SMZL) patients with NOTCH2 mutations, there was a significant decrease in the 5-year OSR (SMD: -11.11, 95% CI: -13.39 to -8.84, P < 0.01) and PFSR (SMD: -23.49, 95% CI: -28.85 to -18.14, P < 0.01). Similarly, TNFAIP3 mutations in SMZL patients demonstrated diminished 5-year OSR (SMD: -14.78, 95% CI: -18.01 to -11.56, P < 0.01) and PFSR (SMD: -21.06, 95% CI: -27.13 to -14.98, P < 0.01). For ocular adnexal MZL (OA-MZL) patients with NOTCH2 mutations, the 5-year OSR significantly declined (SMD: -23.40, 95% CI: -28.87 to -17.93, P < 0.01). Genetic mutations, notably in NOTCH2 and TNFAIP3 genes, have discernable negative implications on the prognosis of MZL patients. Recognizing these genetic markers can guide more personalized therapeutic interventions and inform clinical prognosis.
Appendix
Available only for authorised users
Literature
1.
Smith A et al (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 105(11):1684–1692CrossRefPubMedPubMedCentral
2.
Thieblemont C et al (2014) Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. Sem Cancer Biol 24:33–42CrossRef
3.
Parry M et al (2015) Genetics and Prognostication in Splenic Marginal Zone lymphoma: revelations from deep sequencing. Clin Cancer Res 21(18):4174–4183CrossRefPubMedPubMedCentral
4.
Arribas AJ et al (2012) Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood 119(3):e9–e21CrossRefPubMed
5.
6.
7.
Rossi D et al (2012) The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 209(9):1537–1551CrossRefPubMedPubMedCentral
8.
Clipson A et al (2015) KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia 29(5):1177–1185CrossRefPubMed
9.
Piva R et al (2015) The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia 29(2):503–507CrossRefPubMed
10.
Clipson A et al (2015) mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia, 29(5): pp. 1177–1185
11.
Campos-Martin Y et al (2017) Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma. Haematologica 102(8):e310–e312CrossRefPubMedPubMedCentral
12.
Jallades L et al (2017) Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica 102(10):1758–1766CrossRefPubMedPubMedCentral
13.
Qian L et al (2020) Deletion 20q12 is associated with histological transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma. Am J Hematol 95(3):238–244CrossRefPubMed
14.
Jangam D et al (2020) TBL1XR1 mutations in primary marginal zone lymphomas of Ocular Adnexa are Associated with Unique Morphometric Phenotypes. Curr Eye Res 45(12):1583–1589CrossRefPubMed
15.
Johansson P et al (2020) Identifying genetic lesions in ocular adnexal extranodal marginal zone lymphomas of the MALT subtype by whole genome, whole exome and targeted sequencing. Cancers (Basel), 12(4)
16.
Vela V et al (2020) High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. Hematol Oncol 38(3):284–292CrossRefPubMed
17.
Bonfiglio F et al (2022) Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood 139(5):732–747CrossRefPubMed
18.
19.
Lobry C, Oh P, Aifantis I (2011) Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think. J Exp Med 208(10):1931–1935CrossRefPubMedPubMedCentral
20.
21.
Rossi D et al (2011) Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 118(18):4930–4934CrossRefPubMed
22.
Ngo VN et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115–119CrossRefPubMed
23.
24.
Baldini L et al (1997) Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br J Haematol 99(2):375–378CrossRefPubMed
25.
Metadata
Title
Genetic alterations and their prognostic impact in marginal zone lymphoma: a meta-analysis
Authors
Xijing Li
Yang Lin
Licai An
Publication date
17-01-2025
Publisher
Springer Berlin Heidelberg
Keyword
Lymphoma
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-06175-z

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits